Article Details

Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment - BioSpace

Retrieved on: 2025-02-12 20:58:44

Tags for this article:

Click the tags to see associated articles and topics

Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment - BioSpace. View article details on hiswai:

Excerpt

The Series C raise was led by New Enterprise Associates, with new investor Foresite Capital and a gaggle of existing investors including Bain ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo